Dublin-based Amarin Corp. PLC reached a settlement with Teva Pharmaceutical Industries Ltd. which is looking to sell a copycat version of the company's diet supplement Vascepa.
Amarin had filed a patent infringement lawsuit against the Israeli drug manufacturer after it sought U.S. Food and Drug Administration approval to market icosapent ethyl capsules to adults with hypertriglyceridemia, or elevated fat levels in the blood.
Under the settlement agreement, Teva may start marketing its capsules in the U.S. on Aug. 9, 2029, or earlier under certain customary circumstances. The agreement remains subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Amarin has similar Vascepa patent cases pending against West-Ward Pharmaceutical Corp., Dr. Reddy's Laboratories Inc. and their affiliates in the U.S. District Court for the District of Nevada.
